Integrative Approach to Develop and Characterize Antibodies against the Cancer-Associated Antigen Sialyl Lewis A (CA 19-9)
Anika Freitag, Sana K. Khilji, Ruslan Nedielkov, Shalini M Kumar, Michael Krummhaar, Janine Arndt, Gustavo M. S. G. Moreira, Jost Lühle, Felix Goerdeler, Carsten Kamphues, Maria A. Mroginski, Christian Roth, Peter H. Seeberger, Heiko M. Möller, Oren Moscovitz · 2026
Read Integrative Approach to Develop and Characterize Antibodies against the Cancer-Associated Antigen Sialyl Lewis A (CA 19-9) by Anika Freitag, Sana K. Khilji, Ruslan Nedielkov, Shalini M Kumar, Michael Krummhaar, Janine Arndt, Gustavo M. S. G. Moreira, Jost Lühle, Felix Goerdeler, Carsten Kamphues, Maria A. Mroginski, Christian Roth, Peter H. Seeberger, Heiko M. Möller, Oren Moscovitz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13126176.txt.
Description
Sialyl Lewis A (sLeA), or the CA 19-9 marker, is the best validated and only FDA-approved serologic marker clinically used to monitor recurrence, progression, and therapy efficiency in pancreatic ductal adenocarcinoma (PDAC) patients, making it an attractive target for antibody development.
Catalog record
| CREATOR | Anika Freitag, Sana K. Khilji, Ruslan Nedielkov, Shalini M Kumar, Michael Krummhaar, Janine Arndt, Gustavo M. S. G. Moreira, Jost Lühle, Felix Goerdeler, Carsten Kamphues, Maria A. Mroginski, Christian Roth, Peter H. Seeberger, Heiko M. Möller, Oren Moscovitz |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |